Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence

Hayan Dayoub, Vinod Achan, Shanthi Adimoolam, Johannes Jacobi, Marcus C. Stuehlinger, Bing Yin Wang, Philip S. Tsao, M. Kimoto, Patrick Vallance, Andrew J. Patterson, John P. Cooke

Research output: Contribution to journalArticle

272 Citations (Scopus)

Abstract

Background-NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. Methods and Results-We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed ≈2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. Conclusions-DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity.

Original languageEnglish (US)
Pages (from-to)3042-3047
Number of pages6
JournalCirculation
Volume108
Issue number24
DOIs
StatePublished - Dec 16 2003

Fingerprint

Nitric Oxide
Blood Pressure
Vascular Resistance
Transgenic Mice
Cardiovascular Physiological Phenomena
Nitrogen Oxides
Cardiac Volume
Genetically Modified Animals
Stroke Volume
Blood Vessels
Cultured Cells
Endothelial Cells
dimethylargininase
Enzymes
Genes
In Vitro Techniques
N,N-dimethylarginine

Keywords

  • Blood pressure
  • Endothelium
  • Nitric oxide
  • Risk factors
  • Vasodilation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Dayoub, H., Achan, V., Adimoolam, S., Jacobi, J., Stuehlinger, M. C., Wang, B. Y., ... Cooke, J. P. (2003). Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence. Circulation, 108(24), 3042-3047. https://doi.org/10.1161/01.CIR.0000101924.04515.2E

Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis : Genetic and Physiological Evidence. / Dayoub, Hayan; Achan, Vinod; Adimoolam, Shanthi; Jacobi, Johannes; Stuehlinger, Marcus C.; Wang, Bing Yin; Tsao, Philip S.; Kimoto, M.; Vallance, Patrick; Patterson, Andrew J.; Cooke, John P.

In: Circulation, Vol. 108, No. 24, 16.12.2003, p. 3042-3047.

Research output: Contribution to journalArticle

Dayoub, H, Achan, V, Adimoolam, S, Jacobi, J, Stuehlinger, MC, Wang, BY, Tsao, PS, Kimoto, M, Vallance, P, Patterson, AJ & Cooke, JP 2003, 'Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence', Circulation, vol. 108, no. 24, pp. 3042-3047. https://doi.org/10.1161/01.CIR.0000101924.04515.2E
Dayoub, Hayan ; Achan, Vinod ; Adimoolam, Shanthi ; Jacobi, Johannes ; Stuehlinger, Marcus C. ; Wang, Bing Yin ; Tsao, Philip S. ; Kimoto, M. ; Vallance, Patrick ; Patterson, Andrew J. ; Cooke, John P. / Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis : Genetic and Physiological Evidence. In: Circulation. 2003 ; Vol. 108, No. 24. pp. 3042-3047.
@article{70aaa7505629494083f56b9bdee788fb,
title = "Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence",
abstract = "Background-NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. Methods and Results-We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed ≈2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. Conclusions-DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity.",
keywords = "Blood pressure, Endothelium, Nitric oxide, Risk factors, Vasodilation",
author = "Hayan Dayoub and Vinod Achan and Shanthi Adimoolam and Johannes Jacobi and Stuehlinger, {Marcus C.} and Wang, {Bing Yin} and Tsao, {Philip S.} and M. Kimoto and Patrick Vallance and Patterson, {Andrew J.} and Cooke, {John P.}",
year = "2003",
month = "12",
day = "16",
doi = "10.1161/01.CIR.0000101924.04515.2E",
language = "English (US)",
volume = "108",
pages = "3042--3047",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "24",

}

TY - JOUR

T1 - Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis

T2 - Genetic and Physiological Evidence

AU - Dayoub, Hayan

AU - Achan, Vinod

AU - Adimoolam, Shanthi

AU - Jacobi, Johannes

AU - Stuehlinger, Marcus C.

AU - Wang, Bing Yin

AU - Tsao, Philip S.

AU - Kimoto, M.

AU - Vallance, Patrick

AU - Patterson, Andrew J.

AU - Cooke, John P.

PY - 2003/12/16

Y1 - 2003/12/16

N2 - Background-NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. Methods and Results-We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed ≈2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. Conclusions-DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity.

AB - Background-NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. Methods and Results-We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed ≈2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. Conclusions-DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity.

KW - Blood pressure

KW - Endothelium

KW - Nitric oxide

KW - Risk factors

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=0346365087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346365087&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000101924.04515.2E

DO - 10.1161/01.CIR.0000101924.04515.2E

M3 - Article

C2 - 14638548

AN - SCOPUS:0346365087

VL - 108

SP - 3042

EP - 3047

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 24

ER -